Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 203

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial

Open access
Freeman, Tom P, Hindocha, Chandni, Baio, Gianluca, Shaban, Natacha D C, Thomas, Emily M, Astbury, Danica, Freeman, Abigail M, Lees, Rachel, Craft, Sam, Morrison, Paul D, Bloomfield, Michael A P, O'Ryan, Dominic, Kinghorn, Jane, Morgan, Celia J A, Mofeez, Ali, Curran, H Valerie·2020·The Lancet Psychiatry

Abstract

Background There is a substantial and unmet clinical need for pharmacological treatment of cannabis use disorders. Cannabidiol (CBD) could offer a novel treatment but it is unclear which doses might be effective or safe. Methods Participants meeting DSM-5 cannabis use disorder criteria were allocated to four-week treatment with oral CBD at 200mg, 400mg, 800mg or placebo during a cessation attempt using a double-blinded block randomisation sequence. All received a brief psychological intervention of motivational interviewing. An adaptive Bayesian dose-finding design was used to identify effective/ineffective doses at a priori interim and final analysis stages. The primary objective was to identify the Most Effective Dose (MED) of CBD for reducing cannabis use. The primary endpoint was lower urinary THC-COOH:creatinine concentrations and/or increased days per week abstinent from cannabis during treatment, evidenced by posterior probabilities exceeding Pr=0.9 for CBD versus placebo. All analyses were intention-to-treat. Outcomes Participants were initially randomised to placebo, 200mg, 400mg and 800mg CBD (n=48; 1:1:1:1). At interim analysis 200mg CBD was eliminated from the trial as an ineffective dose. Randomisation continued to 400mg CBD, 800mg CBD, and placebo (n=34; 1:1:1). At final analysis, both 400mg CBD and 800mg CBD exceeded primary endpoint criteria (Pr=0.9) for both primary outcomes: urinary THC-COOH:creatinine (Pr(400mg=MED | Data)=0.9995; Pr(800mg=MED | Data)=0.9965), days per week abstinent from cannabis (Pr(400mg=MED | Data)=0.9966; Pr(800mg=MED | Data)=0.9247). Compared to placebo, 400mg CBD decreased THC-COOH:creatinine concentrations by -94.21 ng/ml (95% Interval Estimate= -161.83, -35.56) and increased abstinence from cannabis by 0.48 days per week (95% Interval Estimate=0.15, 0.82). Compared to placebo, 800mg CBD decreased THC-COOH:creatinine concentrations by -72.02 ng/ml (95% Interval Estimate= -135.47, -19.52) and increased abstinence from cannabis by 0.27 days per week (95% Interval Estimate= -0.09, 0.64). CBD was well tolerated with no severe adverse events and 94% completed treatment. Interpretation In the first randomised clinical trial of CBD for cannabis use disorder, 400mg and 800mg CBD were safe and more effective than placebo at reducing cannabis use. Trial registration https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000361-36/GB

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2215-0366(20)30290-x

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 29

  1. Curran, 2016, Keep off the grass? Cannabis, cognition and addiction, Nat Rev Neurosci, 17, 293, 10.1038/nrn.2016.28 · DOI · Paper page
  2. Degenhardt, 2018, The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet Psychiatry, 5, 987, 10.1016/S2215-0366(18)30337-7 · DOI · Paper page
  3. Freeman, 2019, Increasing potency and price of cannabis in Europe, 2006–16, Addiction, 114, 1015, 10.1111/add.14525 · DOI
  4. Chandra, 2019, New trends in cannabis potency in USA and Europe during the last decade (2008–2017), Eur Arch Psychiatry Clin Neurosci, 269, 5, 10.1007/s00406-019-00983-5 · DOI · Paper page
  5. Freeman, 2015, Examining the profile of high-potency cannabis and its association with severity of cannabis dependence, Psychol Med, 45, 3181, 10.1017/S0033291715001178 · DOI · Paper page
  6. Meier, 2017, Associations between butane hash oil use and cannabis-related problems, Drug Alcohol Depend, 179, 25, 10.1016/j.drugalcdep.2017.06.015 · DOI
  7. Freeman, 2018, Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands, Psychol Med, 48, 2346, 10.1017/S0033291717003877 · DOI
  8. Di Forti, 2019, The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study, Lancet Psychiatry, 6, 427, 10.1016/S2215-0366(19)30048-3 · DOI · Paper page
  9. Bisogno, 2001, Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide, Br J Pharmacol, 134, 845, 10.1038/sj.bjp.0704327 · DOI · Paper page
  10. Freeman, 2019, Medicinal use of cannabis based products and cannabinoids, BMJ, 365
  11. Freeman, 2019, How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review, Neurosci Biobehav Rev, 107, 696, 10.1016/j.neubiorev.2019.09.036 · DOI · Paper page
  12. Hindocha, 2018, Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal, Addiction, 113, 1696, 10.1111/add.14243 · DOI
  13. Hurd, 2019, Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial, Am J Psychiatry, 176, 911, 10.1176/appi.ajp.2019.18101191 · DOI · Paper page
  14. Morgan, 2013, Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings, Addict Behav, 38, 2433, 10.1016/j.addbeh.2013.03.011 · DOI · Paper page
  15. Chesney, 2020, Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials, Neuropsychopharmacology, 10.1038/s41386-020-0667-2 · DOI · Paper page
  16. Shannon, 2015, Cannabidiol oil for decreasing addictive use of marijuana: a case report, Integr Med (Encinitas), 14, 31
  17. Solowij, 2018, Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial, Cannabis Cannabinoid Res, 3, 21, 10.1089/can.2017.0043 · DOI
  18. Allsop, 2015, Cannabinoid replacement therapy (CRT): nabiximols (sativex) as a novel treatment for cannabis withdrawal, Clin Pharmacol Ther, 97, 571, 10.1002/cpt.109 · DOI
  19. Lintzeris, 2019, Nabiximols for the treatment of cannabis dependence: a randomized clinical trial, JAMA Intern Med, 179, 1242, 10.1001/jamainternmed.2019.1993 · DOI
  20. Trigo, 2018, Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial, PLoS One, 13, 10.1371/journal.pone.0190768 · DOI
  21. Zuardi, 2017, Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life, Front Pharmacol, 8, 259, 10.3389/fphar.2017.00259 · DOI · Paper page
  22. Campos, 2008, Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats, Psychopharmacology (Berl), 199, 223, 10.1007/s00213-008-1168-x · DOI · Paper page
  23. Cunha, 1980, Chronic administration of cannabidiol to healthy volunteers and epileptic patients, Pharmacology, 21, 175, 10.1159/000137430 · DOI · Paper page
  24. Kotz, 2013, Predictive validity of the Motivation To Stop Scale (MTSS): a single-item measure of motivation to stop smoking, Drug Alcohol Depend, 128, 15, 10.1016/j.drugalcdep.2012.07.012 · DOI · Paper page
  25. Hindocha, 2016, No smoke without tobacco: a global overview of cannabis and tobacco routes of administration and their association with intention to quit, Front Psychiatry, 7, 104, 10.3389/fpsyt.2016.00104 · DOI · Paper page
  26. Taylor, 2018, A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects, CNS Drugs, 32, 1053, 10.1007/s40263-018-0578-5 · DOI · Paper page
  27. Curran, 2018, Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?, Psychol Med, 49, 1574, 10.1017/S003329171800226X · DOI
  28. Allsop, 2011, The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress, Drug Alcohol Depend, 119, 123, 10.1016/j.drugalcdep.2011.06.003 · DOI · Paper page
  29. Beck, 1961, An inventory for measuring depression, Arch Gen Psychiatry, 4, 561, 10.1001/archpsyc.1961.01710120031004 · DOI · Paper page

Cited by

See all 203

Metadata

Authors
Freeman, T. P., Hindocha, C., Baio, G., Shaban, N. D. C., Thomas, E. M., Astbury, D., Freeman, A. M., Lees, R., Craft, S., Morrison, P. D., Bloomfield, M. A. P., O'Ryan, D., Kinghorn, J., Morgan, C. J. A., Mofeez, A., & Curran, H. V.
Venue
The Lancet Psychiatry
Publisher
Elsevier BV
Published
2020-10
Volume
7
Issue
10
Pages
865-874
ISSN
2215-0366 (ISSN-L)
OpenAlex
W3046002454
Cited by
203
References
10
FWCI
14.85
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • Medical Research Council (MR/K015524/1)
  • Society for the Study of Addiction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. https://app.cochat.ai/papers/10.1016/s2215-0366(20)30290-x
The paper
Freeman, T. P., Hindocha, C., Baio, G., Shaban, N. D. C., Thomas, E. M., Astbury, D., Freeman, A. M., Lees, R., Craft, S., Morrison, P. D., Bloomfield, M. A. P., O'Ryan, D., Kinghorn, J., Morgan, C. J. A., Mofeez, A., & Curran, H. V. (2020). Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(20)30290-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.